KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Other Gross PP&E Adjustments (2016 - 2026)

Gsk has reported Other Gross PP&E Adjustments over the past 18 years, most recently at $11.7 billion for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments rose 10.96% year-over-year to $11.7 billion; the TTM value through Mar 2026 reached $11.7 billion, up 10.96%, while the annual FY2025 figure was $11.4 billion, 6.29% up from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 was $11.7 billion at Gsk, up from $11.4 billion in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $11.7 billion in Q1 2026 and troughed at $2.0 billion in Q1 2022.
  • A 5-year average of $10.0 billion and a median of $10.3 billion in 2024 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 84.01% in 2022 and later soared 393.56% in 2023.
  • Year by year, Other Gross PP&E Adjustments stood at $9.7 billion in 2022, then increased by 3.72% to $10.0 billion in 2023, then rose by 7.22% to $10.8 billion in 2024, then rose by 6.29% to $11.4 billion in 2025, then rose by 1.9% to $11.7 billion in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for GSK at $11.7 billion in Q1 2026, $11.4 billion in Q4 2025, and $11.5 billion in Q3 2025.